Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy Volunteers Jul 7, 2023 | Uncategorized
Exploiting an Interleukin-15 Heterodimeric Agonist (N803) for Effective Immunotherapy of Solid Malignancies Jul 7, 2023 | Cancer
Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial Immunotherapy Jun 29, 2023 | Articles, Colorectal Cancer
IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer Jun 29, 2023 | Bladder Cancer
Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial Feb 28, 2022 | HIV